The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 24, 2017

Filed:

Feb. 04, 2013
Applicant:

Armetheon, Inc., Menlo Park, CA (US);

Inventors:

Peter G. Milner, Los Altos Hills, CA (US);

David J. Ellis, Los Altos, CA (US);

Assignee:

Armetheon, Inc., Milpitas, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/343 (2006.01); A61K 45/06 (2006.01); A61K 31/37 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/439 (2006.01); A61K 31/4402 (2006.01); A61K 31/4418 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/445 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/5377 (2006.01); A61K 31/4184 (2006.01);
U.S. Cl.
CPC ...
A61K 31/343 (2013.01); A61K 31/37 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/4184 (2013.01); A61K 31/439 (2013.01); A61K 31/4402 (2013.01); A61K 31/444 (2013.01); A61K 31/445 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01);
Abstract

The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID.


Find Patent Forward Citations

Loading…